The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Baricitinib: Early vs. Late Treatment Outcomes in RA Patients

Baricitinib: Early vs. Late Treatment Outcomes in RA Patients

August 5, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

MADRID—The results of the 52-week, phase 3 RA-BEGIN study were presented at the 2019 European Congress of Rheumatology (EULAR), June 12–15. During the study, researchers assessed the use of baricitinib monotherapy in patients who received it as early treatment for rheumatoid arthritis (RA). They sought to determine if early treatment with baricitinib resulted in improved clinical, functional and radiographic outcomes compared with patients who used methotrexate monotherapy and later switched to baricitinib.1

You Might Also Like
  • Baricitinib Is Effective in Patients Treated with DMARDs & Methotrexate
  • Baricitinib Has Promising Clinical Trial Results for Treating RA
  • Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA
Explore This Issue
September 2019
Also By This Author
  • Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

The long-term extension study included 588 patients randomized into three groups to receive either methotrexate, 4 mg of baricitinib daily or combination therapy of methotrexate and 4 mg of baricitinib. Patients who were initially randomized to receive baricitinib monotherapy were defined as the early start group, while methotrexate-treated patients who switched to baricitinib at Week 52 were defined as the delayed start group.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study assessed the changes from baseline between the two patient groups from Weeks 0–100. Researchers used the Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Disease Activity Score 28-joints–high-sensitivity C-reactive protein (DAS28-hsCRP), Disease Activity Score 28-joints–Erythrocyte Sedimentation Rate (DAS28-ESR), Health Assessment Questionnaire-Disability Index (HAQ-DI) and modified Total Sharp Score (mTSS; Weeks 52–100). The percentage of patients who achieved low disease activity (SDAI score less than 11) and remission (SDAI score less than 3.3) were also assessed.

The Results
Within the first four weeks of switching to baricitinib therapy, the low disease activity and remission response rates of the delayed-start group increased from 60% to 78% and 18% to 31%, respectively. The remission rates reached 47% within Year 1, which were not different from the earlystart group. Similar results were seen for CDAI, DAS28-ESR and DAS28-hsCRP.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients in the early-start group had significantly greater changes from baseline in HAQ-DI compared with the delayedstart group. These changes were observed as early as Week 1 and continued up to Week 52. This study showed that, in methotrexate-naive RA patients, improved clinical, functional and radiographic efficacy may be achieved with baricitinib.

After the switch to baricitinib, the delayed-start group had a rapid improvement in HAQ-DI, with similar improvement at four weeks. The rate of structural damage also decreased. Delaying baricitinib initiation for a year led to numerically higher mTSS.

At Week 52 when patients were switched from methotrexate to baricitinib, they experienced a rapid clinical response, leading the majority of patients to achieve similar results as early-start patients within four weeks of the switch. If the therapy goal is to attain rapid and sustained disease activity control, the differences in the HAQ-DI and structural progression shown in this study support an earlier switch to baricitinib in patients who do not obtain disease control with methotrexate monotherapy.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: baricitinib, EULAR, Rheumatoid Arthritis (RA)Issue: September 2019

You Might Also Like:
  • Baricitinib Is Effective in Patients Treated with DMARDs & Methotrexate
  • Baricitinib Has Promising Clinical Trial Results for Treating RA
  • Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA
  • RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)